All In Biotech

Drug Trial Radar · NCT05845814

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

A Phase 1/2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab Plus Enfortumab Vedotin (EV) in Combination With Investigational Agents Versus Pembrolizumab Plus EV, as First-Line Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04B

Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 390 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

390

Planned (sponsor's estimate)

Start

Jun 23, 2023

Primary completion

May 31, 2027

Study completion May 31, 2027

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the efficacy and safety of coformulated favezelimab/pembrolizumab plus EV and coformulated vibostolimab/pembrolizumab plus EV relative to pembrolizumab plus EV. There will be no comparison of coformulated favezelimab/pembrolizumab plus EV versus coformulated vibostolimab/pembrolizumab plus EV. If ORR and/or DRR are substantially better on coformulated favezelimab/pembrolizumab plus EV and/or coformulated vibostolimab/pembrolizumab plus EV compared with pembrolizumab plus EV, after evaluation of the totality of data, the sponsor might consider Part 2 (expansion) to further characterize the efficacy and safety of the treatment arms under study.

Conditions

  • Metastatic Urothelial Carcinoma
  • Urothelial Neoplasms

Interventions

  • Coformulated favezelimab/pembrolizumabBiological

    Coformulated favezelimab/pembrolizumab (800 mg/200 mg) IV infusion

  • Coformulated vibostolimab/pembrolizumabBiological

    Coformulated vibostolimab/pembrolizumab (200 mg/200 mg) IV infusion

  • EVCombination product

    1.25 mg/kg IV infusion

  • PembrolizumabBiological

    200 mg IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Objective Response Rate (ORR)Time frame: Up to ~4 years
  2. Part 1: Percentage of Participants experiencing an Adverse Event (AE)Time frame: Up to ~4 years
  3. Part 1: Percentage of Participants who Discontinue study interventions due to an AETime frame: Up to ~4 years
  4. Part 1: Percentage of Participants with Dose-limiting toxicities (DLT)Time frame: Up to 21 days
  5. Part 2: Progression Free Survival (PFS)Time frame: Up to ~4 years

Locations

47 sites in 12 countries. Site status is shown where the registry gives one.

  • Moores Cancer Center ( Site 3028)

    La Jolla, California

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 3045)

    Orange, California

  • UCSF Medical Center at Mission Bay ( Site 3044)

    San Francisco, California

  • Anschutz Cancer Pavilion ( Site 3017)

    Aurora, Colorado

  • Emory University School of Medicine ( Site 3043)

    Atlanta, Georgia

  • Indiana University Melvin and Bren Simon Cancer Center ( Site 3011)

    Indianapolis, Indiana

  • Dana-Farber Cancer Institute ( Site 3047)

    Boston, Massachusetts

  • Siteman Cancer Center ( Site 3038)

    St Louis, Missouri

  • Icahn School of Medicine at Mount Sinai ( Site 3018)

    New York, New York

  • Memorial Sloan Kettering Cancer Center ( Site 3031)

    New York, New York

  • Duke Cancer Institute ( Site 3027)

    Durham, North Carolina

  • Cleveland Clinic-Taussig Cancer Center ( Site 3036)

    Cleveland, Ohio

  • UPMC Hillman Cancer Center ( Site 3014)

    Pittsburgh, Pennsylvania

  • Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 3041)

    Salt Lake City, Utah

  • Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Site 3951)

    Brisbane, Queensland, Australia

  • Austin Health-Cancer Clinical Trials Centre ( Site 3950)

    Heidelberg, Victoria, Australia

  • The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 3105)

    Ottawa, Ontario, Canada

  • Sunnybrook Research Institute - Odette Cancer Centre ( Site 3108)

    Toronto, Ontario, Canada

  • Princess Margaret Cancer Centre ( Site 3106)

    Toronto, Ontario, Canada

  • Bradford Hill Norte ( Site 3152)

    Antofagasta, Chile

  • FALP-UIDO ( Site 3151)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill-Clinical Area ( Site 3155)

    Santiago, Region M. de Santiago, Chile

  • ONCOCENTRO APYS-ACEREY ( Site 3158)

    Viña del Mar, Valparaiso, Chile

  • Hôpital Européen Georges Pompidou ( Site 3605)

    Paris, France

  • CHU de Bordeaux Hop St ANDRE ( Site 3607)

    Bordeaux, Aquitaine, France

  • Centre Georges François Leclerc-Centre de recherche clinique ( Site 3608)

    Dijon, Cote-d Or, France

  • Oncopole Claudius Regaud ( Site 3610)

    Toulouse, Haute-Garonne, France

  • centre hospitalier lyon sud ( Site 3606)

    Pierre-Bénite, Rhone, France

  • Rambam Health Care Campus-Oncology Division ( Site 3501)

    Haifa, Israel

  • Rabin Medical Center-Oncology ( Site 3504)

    Petah Tikva, Israel

  • Sheba Medical Center-ONCOLOGY ( Site 3503)

    Ramat Gan, Israel

  • Ospedale San Raffaele-Oncologia Medica ( Site 3403)

    Milan, Italy

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 3406)

    Naples, Campania, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 3405)

    Milan, Lombardy, Italy

  • Maastricht UMC+ ( Site 3304)

    Maastricht, Limburg, Netherlands

  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 3302)

    Amsterdam, North Holland, Netherlands

  • Erasmus Medisch Centrum-Medical Oncology ( Site 3303)

    Rotterdam, South Holland, Netherlands

  • Severance Hospital, Yonsei University Health System-Medical oncology ( Site 3903)

    Seoul, South Korea

  • Asan Medical Center-Department of Oncology ( Site 3901)

    Seoul, South Korea

  • Samsung Medical Center ( Site 3902)

    Seoul, South Korea

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.